RGEN

Repligen Corporation Common Stock (RGEN)

Stock · NASDAQ · Health Care

$176.27as of 8/28/2026

Active signals

No technical signal is currently active for this symbol.

Support level
$131.21
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Repligen Corporation Common Stock Competitors

Chosen by industry and closest market cap.

  • RGEN
    Repligen Corporation Common Stock
    $176.27
    ▼ 3.16%
    Market cap $8.30BP/E
  • KYMR
    Kymera Therapeutics Inc. Common Stock
    $118.08
    ▼ 1.79%
    Market cap $8.25BP/E
    $39.84$130.05
  • QGEN
    Qiagen N.V. Common Shares
    $43.12
    ▼ 1.43%
    Market cap $8.72BP/E 22.14
    $32.53$57.82
  • HALO
    Halozyme Therapeutics Inc. Common Stock
    $105.33
    ▼ 1.49%
    Market cap $9.76BP/E 27.63
    $61.23$109.66
  • CRSP
    CRISPR Therapeutics AG Common Shares
    $57.69
    ▼ 2.84%
    Market cap $4.78BP/E
    $44.12$78.48
  • ADPT
    Adaptive Biotechnologies Corporation Common Stock
    $25.19
    ▼ 4.73%
    Market cap $3.70BP/E
    $12$26.87
  • RLAY
    Relay Therapeutics Inc. Common Stock
    $18.78
    ▼ 3.30%
    Market cap $3.60BP/E
    $3.5$21.27

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held
63.09M
Total value held
$6.62B
Institutional holders
433
Top holders this quarter
  • Unknown5.99M
  • Unknown4.88M
  • Unknown2.89M
  • Unknown2.77M
  • Unknown2.40M
  • Unknown1.78M
  • Unknown1.53M
  • Unknown1.52M
  • Unknown1.40M
  • Unknown1.37M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.